Want to join the conversation?
Matthew Harrison of Morgan Stanley asks when $VRTX will be able to recognize revenues in France. Chief Medical Officer Jeffrey Chodakewitz said that $VRTX is providing access to Orkambi and it is being paid for that drug in France. He added that from a GAAP perspective, the company is not able to report it and anticipates reporting that in 2017.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?